All patient groups had a family history of cervical cancer; the rates were not high, with the highest being 6.7% in the HER2-enriched group, followed by the TNBC group (5.6%) and the Luminal A group (3.8%), with the lowest in the Luminal B group (3.1%). Here, ERBB2 is linked to cervical carcinoma.